Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How does rHuEPO effect D/P creatinine ratios?

D Richmond1, P Broyan, S Shea

  • 1Good Samaritian Hospital, Baltimore MD.

Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Medical Necessity of Orthodontic Care: A Qualitative Study.

JDR clinical and translational research·2025
Same author

Assessment and treatment of pediatric behavioral sleep disorders in Canada.

Sleep medicine·2018
Same author

SU-E-T-263: Luminescent Dosimetry to Measure the Out-Of-Field Low and High LET Dose Components in High Energy Photon and Proton Therapy Beams.

Medical physics·2017
Same author

WE-G-218-02: The Measurement of Absorbed Dose to Active Intravenous Cardiac Devices in Patients Undergoing Radiotherapy.

Medical physics·2017
Same author

Can't keep that old barium meal down.

Nursing standard (Royal College of Nursing (Great Britain) : 1987)·2016
Same author

Self-reference in psychosis and depression: a language marker of illness.

Psychological medicine·2016
Same journal

Treatment of a Dialysate Leak by Simultaneous Catheter Removal and Replacement in a Patient Undergoing Continuous Ambulatory Peritoneal Dialysis.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

A Rare Complication During Percutaneous Peritoneal Dialysis Catheter Insertion: Intravesical Placement.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

Is It Safe to Initiate Peritoneal Dialysis Treatment Immediately After Percutaneous Catheter Placement?

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

Better Healing of the Exit Site with Negative-Pressure Wound Therapy.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

When Love Hurts, It Leaves No Options! An Unusual Case of Pasteurella Peritoneal Dialysis Peritonitis Causing Severe Intra-abdominal Adhesions Preventing a Future Peritoneal Dialysis Option.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
Same journal

Neisseria mucosa Peritonitis in the Setting of a Migrated Intrauterine Device.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis·2018
See all related articles

Erythropoietin (EPO) therapy in continuous ambulatory peritoneal dialysis (CAPD) patients initially improved peritoneal efficiency but returned to baseline over 27 months. Long-term EPO use may not sustain initial benefits in CAPD patients.

Area of Science:

  • Nephrology
  • Hematology
  • Peritoneal Dialysis

Background:

  • Concerns existed regarding erythropoietin (EPO) use in continuous ambulatory peritoneal dialysis (CAPD) patients due to potential impacts on dialysis efficiency.
  • Previous reports suggested that increased hematocrit from EPO might decrease plasma volume and increase blood viscosity, potentially impairing dialysis.

Purpose of the Study:

  • To assess the long-term effects of EPO therapy on peritoneal membrane function in CAPD patients.
  • To evaluate changes in peritoneal equilibration tests (PET) over an extended period of EPO treatment.

Main Methods:

  • Twelve CAPD patients were studied over 27 months, receiving 4 exchanges daily.
  • Peritoneal equilibration tests (PET) were conducted pre-study and at 3, 6, and 25-27 months.

Related Experiment Videos

  • Patients received subcutaneous EPO (4000 units, 3/week), which effectively raised and maintained hematocrit levels within 12 weeks.

    • Main Results:

    • Initially, D/P creatinine ratios decreased, and ultrafiltration improved with EPO therapy.
    • Over the 27-month study period, D/P creatinine ratios returned to approximately 6% greater than baseline.
    • Hematocrit levels were successfully increased and maintained by EPO treatment.

    Conclusions:

    • While EPO initially enhances peritoneal efficiency in CAPD patients, these benefits may not be sustained long-term.
    • The return of D/P creatinine ratios to baseline suggests potential adaptive mechanisms or other factors influencing peritoneal transport over time.